239 related articles for article (PubMed ID: 34725156)
21. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.
Echeverria I; Liu Y; Gabelli SB; Amzel LM
FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737
[TBL] [Abstract][Full Text] [Related]
22. Molecular mechanism of activation of class IA phosphoinositide 3-kinases (PI3Ks) by membrane-localized HRas.
Siempelkamp BD; Rathinaswamy MK; Jenkins ML; Burke JE
J Biol Chem; 2017 Jul; 292(29):12256-12266. PubMed ID: 28515318
[TBL] [Abstract][Full Text] [Related]
23. Baculovirus production of fully-active phosphoinositide 3-kinase alpha as a p85alpha-p110alpha fusion for X-ray crystallographic analysis with ATP competitive enzyme inhibitors.
Sinnamon RH; McDevitt P; Pietrak BL; Leydon VR; Xue Y; Lehr R; Qi H; Burns M; Elkins P; Ward P; Vincentini G; Fisher D; Grimes M; Brandt M; Auger KR; Ho T; Johanson K; Jones CS; Schwartz B; Sweitzer TD; Kirkpatrick RB
Protein Expr Purif; 2010 Oct; 73(2):167-76. PubMed ID: 20457255
[TBL] [Abstract][Full Text] [Related]
24. Interaction of Calmodulin with the cSH2 Domain of the p85 Regulatory Subunit.
Wang G; Zhang M; Jang H; Lu S; Lin S; Chen G; Nussinov R; Zhang J; Gaponenko V
Biochemistry; 2018 Mar; 57(12):1917-1928. PubMed ID: 29494137
[TBL] [Abstract][Full Text] [Related]
25. Autophosphorylation of serine 608 in the p85 regulatory subunit of wild type or cancer-associated mutants of phosphoinositide 3-kinase does not affect its lipid kinase activity.
Layton MJ; Saad M; Church NL; Pearson RB; Mitchell CA; Phillips WA
BMC Biochem; 2012 Dec; 13():30. PubMed ID: 23270540
[TBL] [Abstract][Full Text] [Related]
26. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.
Mandelker D; Gabelli SB; Schmidt-Kittler O; Zhu J; Cheong I; Huang CH; Kinzler KW; Vogelstein B; Amzel LM
Proc Natl Acad Sci U S A; 2009 Oct; 106(40):16996-7001. PubMed ID: 19805105
[TBL] [Abstract][Full Text] [Related]
27. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R).
Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH
J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696
[TBL] [Abstract][Full Text] [Related]
28. Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.
Varkaris A; Pazolli E; Gunaydin H; Wang Q; Pierce L; Boezio AA; Bulku A; DiPietro L; Fridrich C; Frost A; Giordanetto F; Hamilton EP; Harris K; Holliday M; Hunter TL; Iskandar A; Ji Y; Larivée A; LaRochelle JR; Lescarbeau A; Llambi F; Lormil B; Mader MM; Mar BG; Martin I; McLean TH; Michelsen K; Pechersky Y; Puente-Poushnejad E; Raynor K; Rogala D; Samadani R; Schram AM; Shortsleeves K; Swaminathan S; Tajmir S; Tan G; Tang Y; Valverde R; Wehrenberg B; Wilbur J; Williams BR; Zeng H; Zhang H; Walters WP; Wolf BB; Shaw DE; Bergstrom DA; Watters J; Fraser JS; Fortin PD; Kipp DR
Cancer Discov; 2024 Feb; 14(2):240-257. PubMed ID: 37916956
[TBL] [Abstract][Full Text] [Related]
29. The mechanism of PI3Kα activation at the atomic level.
Zhang M; Jang H; Nussinov R
Chem Sci; 2019 Mar; 10(12):3671-3680. PubMed ID: 30996962
[TBL] [Abstract][Full Text] [Related]
30. Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85α regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain.
Hofmann BT; Jücker M
Cell Signal; 2012 Oct; 24(10):1950-4. PubMed ID: 22735814
[TBL] [Abstract][Full Text] [Related]
31. Assembly and Molecular Architecture of the Phosphoinositide 3-Kinase p85α Homodimer.
LoPiccolo J; Kim SJ; Shi Y; Wu B; Wu H; Chait BT; Singer RH; Sali A; Brenowitz M; Bresnick AR; Backer JM
J Biol Chem; 2015 Dec; 290(51):30390-405. PubMed ID: 26475863
[TBL] [Abstract][Full Text] [Related]
32. Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases.
Sabbah DA; Vennerstrom JL; Zhong H
J Chem Inf Model; 2010 Oct; 50(10):1887-98. PubMed ID: 20866085
[TBL] [Abstract][Full Text] [Related]
33. Structural Perturbations due to Mutation (H1047R) in Phosphoinositide-3-kinase (PI3Kα) and Its Involvement in Oncogenesis: An in Silico Insight.
Sharma J; Bhardwaj V; Purohit R
ACS Omega; 2019 Oct; 4(14):15815-15823. PubMed ID: 31592171
[TBL] [Abstract][Full Text] [Related]
34. Insight into the mechanism of allosteric activation of PI3Kα by oncoprotein K-Ras4B.
Li X; Dai J; Ni D; He X; Zhang H; Zhang J; Fu Q; Liu Y; Lu S
Int J Biol Macromol; 2020 Feb; 144():643-655. PubMed ID: 31816384
[TBL] [Abstract][Full Text] [Related]
35. Computational Insights into the Interactions between Calmodulin and the c/nSH2 Domains of p85α Regulatory Subunit of PI3Kα: Implication for PI3Kα Activation by Calmodulin.
Ni D; Liu D; Zhang J; Lu S
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29300353
[TBL] [Abstract][Full Text] [Related]
36. Cryo-EM structures reveal two allosteric inhibition modes of PI3Kα
Huang X; Wang K; Han J; Chen X; Wang Z; Wu T; Yu B; Zhao F; Wang X; Li H; Xie Z; Zhu X; Zhong W; Ren X
Structure; 2024 Mar; ():. PubMed ID: 38582077
[TBL] [Abstract][Full Text] [Related]
37. Cloning, expression, purification, and characterization of the human Class Ia phosphoinositide 3-kinase isoforms.
Meier TI; Cook JA; Thomas JE; Radding JA; Horn C; Lingaraj T; Smith MC
Protein Expr Purif; 2004 Jun; 35(2):218-24. PubMed ID: 15135396
[TBL] [Abstract][Full Text] [Related]
38. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
Dornan GL; Burke JE
Front Immunol; 2018; 9():575. PubMed ID: 29616047
[TBL] [Abstract][Full Text] [Related]
39. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755
[TBL] [Abstract][Full Text] [Related]
40. The structural basis for Ras activation of PI3Kα lipid kinase.
Zhang M; Jang H; Nussinov R
Phys Chem Chem Phys; 2019 Jun; 21(22):12021-12028. PubMed ID: 31135801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
